TrialJAMA oncology2020

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

Heikki Joensuu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.